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Abstract
Introduction: In the search for markers of invasiveness of pituitary adenomas, we studied the expression of Ki-67 antigen, TOPO 2A 
(topoisomerase 2 alpha), AIP (Aryl Hydrocarbon Receptor-Interacting Protein), and VEGF (Vascular Endothelial Growth Factor) in so-
matotropinomas.
Material and methods: We retrospectively studied a group of 31 patients who underwent pituitary tumour surgery. Expression of Ki-67, 
TOPO 2A, AIP, and VEGF in surgical specimens was determined by immunohistochemistry. Relations between quantitatively determined 
markers and clinical symptoms, tumour features, and MR imaging, were analysed. Acromegaly was confirmed by hormonal tests in all 
patients studied. Local invasiveness (cavernous sinus penetration, optic chiasm compression or suprasellar extension) was observed in 
18/31 patients (58.1%). 
Results: Ki-67 was expressed in 77.4%, TOPO 2A in 87.1%, AIP in 83.8%, and VEGF in 87.1% of 31 cases of somatropinoma. Median values 
of Ki-67, TOPO 2A, AIP, and cytoplasmic VEGF indices, were 1.2% [IQR = 2.2], 1.5% [IQR = 1.6], 21.26% [IQR = 20.1], and 20.4% [IQR 
= 15.4], respectively. 
Ki-67, TOPO 2A, AIP, and VEGF expression was not correlated with age nor with patient gender (p > 0.05). Only Ki-67 and TOPO 2A 
correlated with tumour size (for Ki-67: r = 0.42, p = 0.025; for TOPO 2A: r = 0.53, p = 0.003). Ki-67 and TOPO 2A levels were significantly 
higher in invasive compared to noninvasive somatropinomas (Ki-67 mean values: 1.85 ± 1.33% vs. 0.95 ± 1.07%, p = 0.024; TOPO 2A 
mean values: 2.19 ± 1.63% vs. 1.45 ± 1.23%, p = 0.011). 
Conclusions: Ki-67, TOPO 2A, AIP, and VEGF were expressed in over 70% of all somatotropinomas. Only Ki-67 and TOPO 2A expression 
correlated with tumour size and tumour invasiveness. (Endokrynol Pol 2018; 69 (2): 182–189)
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Streszczenie 
Wstęp: W poszukiwaniu markerów inwazyjności gruczolaków przysadki badano ekspresję antygenu Ki-67, TOPO 2A (topoisomerase 2 alpha), 
AIP (Aryl Hydrocarbon Receptor-Interacting Protein) oraz VEGF (Vascular Endothelial Growth Factor) w guzach wydzielających hormon wzrostu. 
Materiał i metody: Badano retrospektywnie grupę 31 pacjentów, operowanych z powodu guza przysadki. Ekspresję Ki-67, TOPO 2A, 
AIP oraz VEGF badano immunohistochemicznie w tkankach uzyskanych chirurgicznie. Analizowano relacje między ilościową ekspresją 
markerów a objawami klinicznymi, cechami guza i obrazem MR. Testami hormonalnymi potwierdzono akromegalię u wszystkich bada-
nych pacjentów. Miejscową inwazyjność, zdefiniowaną jako naciekanie zatoki jamistej, kompresję skrzyżowania wzrokowego, wzrost 
nadsiodłowy guza obserwowano u 18/31 (58,15) pacjentów. 
Wyniki: Ekspresję Ki-67 stwierdzono w 77,4%, TOPO 2A w 87,1%, AIP w 83,8%, oraz VEGF w 87,1% przypadków samatotropinoma 
(n = 31). Wartości median indeksów Ki-67, TOPO 2A, AIP i cytoplazmatycznego VEGF wynosiły 1,2% [IQR = 2,2], 1,5% [IQR = 1,6], 
21,26% [IQR = 20,1] i 20,4% [IQR = 15,4], odpowiednio. Indeksy Ki-67, TOPO 2A, AIP i VEGF nie korelowały z wiekiem i płcią pacjentów 
(p > 0,05). Tylko Ki-67 i TOPO 2A korelowało z wielkością guza (dla Ki-67: r = 0,42, p = 0,025; dla TOPO 2A: r = 0,53, p = 0,003). Indeksy 
Ki-6 oraz TOPO 2A były znamiennie wyższe w guzach inwazyjnych w porównaniu z guzami nieinwazyjnymi (średnie Ki-67: 1,85 ± 1,33% 
vs 0,95 ± 1,07%, p = 0,024 oraz średnie TOPO 2A: 2,19 ± 1,63% vs 1,45 ± 1,23%, p = 0,011). 
Wnioski: Ekspresję Ki-67, TOPO 2A, AIP i VEGF stwierdzono w ponad 70% wszystkich somatotropinoma. Tylko ekspresja Ki-67 oraz 
TOPO 2A korelowała z wielkością guza i jego inwazyjnością. (Endokrynol Pol 2018; 69 (2): 182–189)
Słowa kluczowe: gruczolak przysadki, markery proliferacji, Ki-67, TOPO 2A, AIP, VEGF
Introduction
Somatotropinomas form 15–20% of all pituitary adeno-
mas (PAs). The estimated frequency of acromegaly is 
50–70 cases/million [1, 2]. Although mainly benign, PAs 
with invasive growth (30–45%), recurrence, resistance to 
multimodal treatment, and “atypical” morphologic fea-
tures, are considered as being clinically aggressive [3, 4]. 
Dr hab. n. med. Agata Baldys-Waligorska, Department of Endocrinology, Faculty of Medicine Jagiellonian University, Medical College, Mikolaja 
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However, their invasiveness is not clearly defined in 
WHO 2004 classification, which distinguishes only 
between typical and atypical adenomas (characterised 
by invasive growth, increased mitotic index, Ki-67 
> 3%, and extensive nuclear expression of p53), and 
carcinomas [5–7].
Markers of proliferation and angiogenesis, over-
expression of which was found in PAs, are potential 
indicators of tumour behaviour. Apart from the well-
documented Ki-67, TOPO 2A (topoisomerase 2A), AIP 
(Aryl Hydrocarbon Receptor-Interacting Protein), and 
VEGF (Vascular Endothelial Growth Factor) have been 
suggested. 
Ki-67 is a nuclear antigen expressed in all cell cycle 
phases, except G0; therefore, it is recognised as a pro-
liferation marker. In pituitary tumours, Ki-67 indices 
may vary between < 1% and 23%, and do not correlate 
with tumour size [8]. A high Ki-67 index, as a marker 
of proliferation in atypical adenomas, does not appear 
to be reliable in predicting tumour recurrence [7–9]. 
TOPO 2A is one of the key enzymes in DNA replica-
tion and cell division [10], indicating rapid cell prolifera-
tion in many tumours [11–13]. In PAs, strong correlation 
between MIB1 and TOPO 2A expression was found [13]. 
AIP, encoded by a suppressor gene, is present in the 
nucleus and cytoplasm of many human tissues, e.g. 
heart, brain, or tonsils. AIP is involved in many, but 
not fully understood, cellular pathways [15]. Germline 
mutations of AIP are associated with familial isolated 
pituitary adenoma (FIPA) secreting hGH and/or PRL, 
found in young patients [16]. There are no somatic AIP 
mutations [17]. Mutant AIP loses the ability to reduce 
cell proliferation. AIP expression has also been shown 
to be a predictor of response to octreotide LAR (SSLAR) 
therapy, independently of somatostatin receptor type 2 
(SSTR2) expression [18].
VEGF is an angiogenic factor expressed in the cyto-
plasm and nucleus in many solid tumours, stimulating 
cell proliferation and migration, increasing vascular 
permeability, being associated with the development of 
metastases and poor prognosis [19]. However, the role 
of angiogenesis in the pituitary is not clear as PAs are 
less vascularised compared to other tumours and to the 
normal pituitary gland. Higher VEGF expression in PAs 
than in normal tissue has been shown [20]; however, 
the results are not conclusive as different methods were 
used. VEGF is presumed to be a biomarker of pituitary 
neoplasms [8, 16]. 
Prediction of pituitary tumour behaviour and 
disease recurrence after neurosurgery is still a chal-
lenge. To treat patients more effectively, optimal and 
standardised markers of invasiveness and prolifera-
tion of PAs are being sought. Selection of patients with 
aggressive tumours based on immunohistochemistry 
and molecular studies is essential for individualised 
treatment. Therefore, in this work we studied the cor-
relation of selected markers with tumour invasiveness, 
progression, and recurrence. 
Materials and methods
We retrospectively studied clinical, histopathology, 
and immunohistochemistry records of 31 patients of 
our Clinic of Endocrinology, who underwent pituitary 
surgery (transsphenoidal resection and/or craniotomy, 
with 42% of patients successfully operated), between 
1997 and 2008, followed up for 24 and 36 months. Eleven 
patients were treated with SSLAR before surgery. The 
PA diagnosis was based on clinical, biochemical, and 
radiological data, confirmed by surgery and histo-
pathology examinations. Table I presents our patient 
characteristics. 
Tumour size, defined as its largest dimension and 
its relation to adjacent tissues, was evaluated by 1.5 T 
MR images obtained prior to surgery, 12 months, and 
24–36 months after surgery. Tumour invasiveness was 
defined according to radiological criteria of Knosp [21] 
and Zada [22] and surgeon descriptions, as given in 
patient records. Recurrence was defined as a new le-
sion or enlargement of residual pituitary adenoma in 
MRI after surgery. 
The surgical specimens were routinely processed, 
fixed in neutral buffered formalin, embedded in par-
affin, cut into 4 µm-thick slides, and stained with H-E. 
Specific primary antibodies (Dako, Glostrup, Denmark) 
were used against pituitary hormones: ACTH, GH, PRL, 
TSH, LH, and FSH.
For immunohistochemistry (IHC), sections were in-
cubated with the following antibodies: primary mouse 
monoclonal antibody Ki-67, clone MIB-1 antibody 
(Dako, M7240, in optimum dilution 1:25), Novocastra 
primary mouse monoclonal antibody Topisomerase 2A, 
clone 3F6 (NCL-TOPO 2A, Leica Biosystems, 1:100), 
primary mouse monoclonal antibody AIP, clone LS-B227 
(LSBio, 1:300), and primary rabbit monoclonal antibody 
VEGF, clone SP28 (Thermo Fisher Scientific, 1:100). 
Manufacturer’s recommendations were followed for 
each antibody. Control of specificity of the primary 
antibody, and positive/negative control tests were per-
formed according to the manufacturer’s instructions.
Immunostained sections were evaluated by optical 
microscopy (NIKON OPTISHOT-2). Ten fields were 
selected in regions of highest concentration of posi-
tive cells and examined at 400x magnification. A total 
of at least 2000 cells were viewed in each section. The 
labelling index (LI) was evaluated as the percentage of 
positive cells — stained nuclei for Ki-67 and TOPO 2A, 
or stained cytoplasm for AIP and VEGF. 
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Local invasiveness (cavernous sinus penetration, 
optic chiasm compression, or suprasellar extension) oc-
curred in 18/31 patients (58,1%). There was a significant 
Table I. Patients’ characteristics
Tabela I. Charakterystyka pacjentów
General data Age: mean ± SD [y] 43 ± 14.3
Gender: Female/male (%) 20 (64.5%)/11 (35.5%)
Microadenoma (%)
Macroadenoma (%)
8 (26.0%)
23 (74.0%)
Size of tumour [mm]
Median [IQR]/mean ± SD
16 [14.4]/22.2 ± 20.7
Local invasion of tumor 18 (58.1%)
Compression/dislocation 
or modeling of the optic 
chiasm (%)
10 (32%)
Sella turcica destruction 5 (16.1%)
Cavernous sinus 
penetration
15 (48.4%)
Suprasellar propagation 14 (45.1%)
Complete surgery 13/31 (42%)
Radiological 
progression/
recurrence in 
MRI (patients (%)
after 12 months 6/31 (19.35%)
after 36 months 5/31 (16.13%)
Immunohistoche-
mical findings*
(n = 31)
Number of 
patients/(%)
Hormonal positivity 29 (93.7%)
NCA 1 (3.2%)
GH positive 27 (87.1%)
PRL positive 18 (58.1%)
ACTH positive 7 (22.6%)
TSH positive 7 (22.6%)
FSH positive 4 (12.9%)
LH positive 2 (6.5%)
Plurihormonal 12 (38.7%)
Histopathological features 
of malignancy*
 4 (12.9%)
Hormones 
before surgery
hGH median [IQR]
(min-max) [ng/ml]
18.5 [19.8]/
(2.8–170.0)
IGF-1 median [IQR ]
(min-max) [ng/ml]
768.0 [610.2]
(174.9–1999.0)
**ULN median (min-max) 2.23 (0.40–4.33)
Hormones 
after surgery
hGH median [IQR] 
(min-max) [ng/ml]
2.25[4.0] 
(0.45–50.0)
IGF-1 median [IQR] 
(min-max) [ng/ml]
267.0 [319.5] 
(43.3–980.0)
**ULN median (min-max) 0.65 (0.14–2.32)
*Pituitary adenomas were classified according to WHO 2004 classification
**ULN — upper limit of normal IGF-1 concentration
n = 31, y — years
The study was approved by the Local Bioethics 
Committee of the Jagiellonian University Medical 
College (KBET/84/B/2012).
Basic statistical and comparative analyses appro-
priate to the distributions of data were performed. 
Kolmogorov-Smirnov, Mann-Whitney, Kruskal-Wallis, 
analysis of variance, T-test, Wilcoxon test, and Fischer 
exact tests were applied. Relative risk (RR) was calcu-
lated based on χ2 frequency tables. Linear regression 
was applied to evaluate the correlation of normally 
distributed variables (n ≥ 30). Otherwise, non-para-
metric Spearman rank correlation test was applied. For 
Kaplan-Meier (time-to-incidence plot with 36 months 
as the last follow-up point) and receiver operating char-
acteristic (ROC) plots, GraphPad Prism version 5.03 for 
Windows (GraphPad Software, San Diego California, 
United States) was used. To establish predictors of recur-
rence and pituitary tumour advancement, Cox multiple 
regression and logistic regression were generated using 
the Statsdirect version 2.0 for Windows (Statsdirect Ltd., 
Cheshire, United Kingdom). P values of 0.05 or less were 
considered as being statistically significant. 
Results
Median concentrations of hGH and IGF-1 decreased sig-
nificantly after surgery (p < 0.05) (Table I). No correla-
tion was found between hGH and IGF-1 concentration 
and tumour size prior to and after surgery (p > 0.05). 
The percentage of adenomas (n = 31) with positive 
immunostaining for Ki-67, TOPO 2A, AIP, and VEGF 
was 24 (77.4%), 27 (87.1%), 26 (83.9%), and 27 (87.1%), 
respectively (Figure 1).
Mean and median values of studied indices are 
given in Table II. 
In micro- and macroadenomas, expression of Ki-
67 differed significantly with median values of 0.00% 
[IRQ = 1.32] and 1.45% [IQR = 1.81], respectively 
(p = 0.0155) (Figure 2). Expression of Ki-67 exceeding 
3% was observed in 3/31 tumours (9.7%). The maxi-
mum value of Ki-67 observed in one macroadenoma 
was 4.94%. Similarly, there was a significant difference 
between TOPO 2A expression in micro- and macroad-
enomas, with mean values of 0.71 ± 0.77% and 2.22 ± 
1.50%, respectively (p = 0.001) (Figure 2). However, 
there was no difference in AIP and VEGF expression. 
No correlation between age or gender and Ki-67, 
TOPO 2A, AIP, and VEGF expression was found (p 
> 0.05). However, there was a significant correlation 
between tumour size and expression of Ki-67 (r = 0.42, 
p = 0.025) and TOPO 2A (r = 0.53, p = 0.003). No cor-
relation of AIP and VEGF with tumour size was noted. 
Interestingly, a correlation between Ki-67 and TOPO 2A 
indices was observed (r = 0.46, p = 0.01).
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difference between mean values of Ki-67 index in invasive 
vs. non-invasive tumours: 1.85 ± 1.33% vs. 0.95 ± 1.07%, 
respectively (p = 0.024) (Figure 3). Similarly, there was 
a significant difference between mean TOPO 2A index 
values in invasive vs. non-invasive tumours: 2.19 ± 1.63% 
vs. 1.45 ± 1.23%, respectively (p = 0.011) (Figure 3).
Local recurrence/progression of the tumour, based 
on MRI evaluation after 12 and 36 months, occurred in 
11 patients (35.5%). There was no difference in median 
values of the studied markers between recurrent and 
non-recurrent adenomas.
In ROC curve analysis, no cut-off point values were 
statistically significant for any marker. Therefore, we 
arbitrarily selected the following cut-off points: Ki-67 — 
1%, TOPO 2A — 1%, VEGF — 10%, and AIP — 15%. 
On the plot of cumulated hazard, we tested whether 
expression of these markers above such cut-off points af-
fected the frequency of disease recurrence. No significant 
difference was found for any marker. Using Cox multiple 
regression analysis, we calculated the relative risk (RR) of 
tumour recurrence depending on labelling index — no 
significant risk was found above these thresholds, except 
for AIP — above 15%, with RR = 3.85 (95% CI 71.96-98.93).
In 11 patients treated preoperatively with SSLAR 
(20–30 mg monthly) no expression of any of the mark-
ers was significantly affected. However, LI of VEGF was 
markedly lower in SSLAR-treated patients: 9.6% [8.79] 
vs. non-treated: 23.78% [23.24] (p = 0.075) (Table III).
Discussion 
In the search for new markers of invasiveness, prolifera-
tion and angiogenesis in pituitary adenomas based on 
molecular mechanisms involved in uncontrolled cell 
proliferation and tumour growth, of particular inter-
est are biomarkers that reliably predict the biological 
behaviour, allowing for targeted therapies. 
We investigated the expression of Ki-67, TOPO 2A, AIP, 
and VEGF as proliferation markers of somatotropinomas 
Figure 1. Immunohistochemical stainning for studied markers of proliferation and invasion in pituitary adenomas, magnitude 200x: 
A. Ki-67 nuclear staining; B. TOPO 2A — nuclear staining; C. AIP diffuse cytoplasmic immunostaining; D. VEGF — diffuse 
cytoplasmic immunostaining
Rycina 1. Ekspresja badanych markerów proliferacji i inwazyjności w gruczolakach przysadki — barwienie immunohistochemiczne, 
powiększenie mikroskopowe 200x: A. Ki-67 barwienie jądrowe; B. TOPO 2A — barwienie jądrowe; C. AIP — rozlane barwienie 
cytoplazmatyczne; D. VEGF — rozlane barwienie cytoplazmatyczne
A B
C D
Table II. Mean and median values of labelling indices of the 
studied markers
Tabela II. Mediany i wartości średnie indeksów barwienia 
dla badanych markerów
Parameter Mean value ± SD Median value [IQR]
Ki-67 1.5% ± 1.3 1.2% [IQR = 2.2]
TOPO 2A 1.9% ± 1.5 1.5% [IQR = 1.6]
AIP 26.1 ± 21.3 21.2 % [IQR = 20.1]
VEGF 21.4% ± 15.9 20.4% [IQR = 15.4]
186
PR
A
C
E 
O
RY
G
IN
A
LN
E
Proliferation markers in somatotropinomas Agata Baldys-Waligorska et al.
in patients who underwent neurosurgery. We evaluated 
the relationship between these markers and patient 
demographic data and between tumour features to 
establish their prognostic value and indication for reop-
eration or radiotherapy. We also analysed the effect of 
preoperative treatment with SSLAR on the expression 
of the studied markers. 
Expression of investigated markers
The percentage of adenomas with positive immu-
nostaining for Ki-67 in the study group was over 77% as 
compared to 88% or 100% as reported by other authors 
[23, 24]. In our study somatotropinomas presented gene-
rally with Ki-67 index < 3%, and high variation (range 
Figure 2A. Expression of TOPO 2A in micro- and macro-adenomas secreting hGH (mean ± SD of LI); B. Expression of Ki-67 in 
micro- and macro-adenomas secreting hGH (median [IQR] of LI)
Rycina 2A. Ekspresja TOPO 2A w mikro- i makrogruczolakach przysadki wydzielających hGH (wartości średnie ± SD LI); B. Ekspresja 
Ki-67 w mikro- i makrogruczolakach przysadki wydzielających hGH (mediany [IQR] LI)
Figure 3A. Expression of Ki-67 in non-invasive and invasive somatotropinomas (mean ± SD of LI); B. Expression of TOPO 
2A in non-invasive and invasive somatotropinomas (mean ± SD of LI); 0 — non-invasive somatotropinomas; 1 — invasive 
somatotropinomas
Rycina 3A. Ekspresja Ki-67 w nieinwazyjnych i inwazyjnych gruczolakach przysadki wydzielających hGH (wartości średnie ± SD); 
B. Ekspresja TOPO 2A w nieinwazyjnych i inwazyjnych gruczolakach przysadki wydzielających hGH (wartości średnie ± SD); 
0 — nieinwazyjne somatotropinoma; 1 — inwazyjne somatotropinoma
Table III. Expression of studied markers (LI) in patients 
treated (n = 11 patients) and non-treated with SSLAR prior 
to surgery of pituitary adenoma
Tabela III. Ekspresja badanych markerów (LI) w grupie 
pacjentów leczonych (n = 11) i nieleczonych SSLAR przed 
operacją gruczolaka przysadki
Marker Non-treated  
median  
[IQR]
Treated  
median  
[IQR]
P*
Ki-67 1.3% [2.25] 2.03% [2.57] 0.78
TOPO 2A 1.49% [1.9] 1.27% [2.11] 0.39
AIP 23.3% [32.4] 18.03% [19.76] 0.56
VEGF 23.78% [23.24] 9.6% [8.79] 0.075
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0–4.94%), with values exceeding 3% in only three atypical 
tumours. In a group of predominantly non-functioning 
adenomas, Ki-67 indices ranged from 1% to 4.8% [24] and 
from 1.4% to 5.2% in somatotropinomas [25]. 
TOPO 2A-positive immunostaining in our somato-
tropinomas was higher than that in patients with dif-
ferent types of PAs [11, 13], where values of the TOPO 
2A index ranged from 0% to 3.5%, with a median value 
of about 0.7% [13, 26], against our median LI of 1.5%.
AIP expression in somatotropinomas is ambigu-
ous. AIP mutations were detected in 2–4% of young 
acromegalic patients with sporadic microadenoma and 
macroadenoma [17]. In our sporadic somatotropinomas 
AIP was positive in over 80% of tumours, which is in line 
with other studies [27], while Kasuki et al. found low 
expression in only about 50% of somatotropinomas [18]. 
VEGF immunostaining in normal pituitary glands was 
higher than in adenomas, with greater expression in pi-
tuitary carcinomas in relation to adenomas [28], while the 
highest expression of VEGF was found in non-functioning 
and GH-producing adenomas. On the other hand, in 
a RT-PCR study of different subtypes of pituitary adeno-
mas, somatotropinomas showed lowest VEGF expression 
[29, 30]. In IHC, expression of VEGF was decreased in 
somatotropinomas, against normal tissue [31]. 
We note the difficulty of comparing our AIP and 
VEGF results with those of other authors who analysed 
different types of PAs using different evaluation meth-
ods. In our view, the particular value of our investiga-
tion is in its relatively large and homogeneous group 
of GH-secreting adenomas.
Age and gender
In our group of somatotropinomas we found no correla-
tion between age and gender, and values of the studied 
markers. In other studies of GH-secreting adenomas, 
Ki-67 index depended on gender but not on patient 
age [32]. Results concerning TOPO 2A expression are 
generally inconclusive: Vidal et al. [11] found negative 
correlation between TOPO 2A expression and patient 
age and no correlation with patient gender, while else-
where TOPO 2A expression did not depend on patient 
age [13, 14]. Age and gender and adenoma type did not 
affect AIP [18] and VEGF expression [31].
Tumour size
We found clear correlation between values of Ki-67 
and TOPO 2A indices and tumour size, the difference 
between values of Ki-67 and TOPO 2A in micro- and 
macro-adenomas being statistically significant. How-
ever, lack of correlation between Ki-67 expression and 
tumour size was also reported [8]. Elsewhere, higher 
TOPO 2A expression was shown in non-functioning 
macroadenomas, which correlated with tumour size [13], 
while no correlation between TOPO 2A expression 
and tumour size [14], or even negative correlation [11] 
were also observed. A low AIP score was found in 
large somatotropinomas [33]. No correlation of VEGF 
expression with tumour size was stated [29, 31], which 
our study confirms. 
Invasiveness
Local invasion and infiltration of the adjacent structures, 
postoperative regrowth or persistence of hormonal 
function are potential indicators of PA aggressiveness 
[11, 13, 21, 22]. In our study Ki-67 and TOPO 2A indices 
were significantly higher in invasive vs. non-invasive 
somatotropinomas. Determination of TOPO 2A activity 
enabled a group of invasive pituitary adenomas to be 
distinguished [11, 13]. However, no advantage of TOPO 
2A over Ki-67 was stated [11]. In the work of Kasuki et 
al. [34] the range of Ki-67 index in invasive somatotro-
pinomas (0–20.6%) was much wider than that in our 
group, with a 2.3% cut-off point on their ROC curve. 
Other investigators found no correlation between 
Ki-67 index and somatotropinoma invasiveness [35, 36]. 
Nevertheless, the opinion prevails that radiological 
grading, IHC classification, and Ki-67 as prognostic 
markers are important in evaluating the true nature of 
atypical pituitary adenomas [4, 5, 7, 16, 23, 37].
In our somatotropinomas there was no significant 
difference between mean values of AIP and VEGF 
indices in invasive vs. non-invasive tumours. In some 
50% of sporadic adenomas, low intrinsic AIP expression, 
predominant invasiveness, and poor response to soma-
tostatin analogues (SSA) are observed [27, 33, 34, 38], 
especially in patients with confirmed AIP mutation 
[27]. While in somatropinomas AIP was claimed to 
be a better marker of invasiveness than Ki-67 and p53 
[34], its expression varied widely in our study and 
elsewhere [27].
In agreement with Kurosaki et al. [31], we found no 
difference in VEGF expression between invasive and 
non-invasive tumours, as opposed to the suggested 
VEGF LI above 25% as a cut-off value for invasive soma-
totropinomas [36]. Higher VEGF expression was seen in 
invasive non-functioning giant adenomas and tumours 
with extrasellar growth [25, 29], in contrast to low VEGF 
expression in patients, 70% of whom achieved remis-
sion [35]. We may thus presume that VEGF plays an 
indirect role in the development of somatotropinomas, 
being an independent stimulator of angiogenic growth 
and progression in GH-secreting adenomas. 
Tumour recurrence
In our study, no differences between median values of 
relevant indices for any marker were found, nor could 
any cut-off points be established for recurrent and 
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non-recurrent adenomas. Therefore, in our cohort, no 
relation between these parameters and clinical outcome 
could be demonstrated. 
However, we noted after 12 months of observation 
that recurrences occurred in all and in almost all adeno-
mas in which Ki-67 and TOPO 2A indices exceeded the 
arbitrarily chosen cut-off points of 1%. 
In our group of somatotropinomas, in only three 
patients (9.7%) did Ki-67 index exceed 3%, this patient 
number not being statistically significant. The role of 
Ki-67 as a marker of recurrence in pituitary tumours is 
not established. In small and non-homogenous patient 
groups with non-functioning PAs and somatotropino-
mas, expression of Ki-67 was not related to tumour re-
currence nor to local invasion [23, 24]. Magagna-Poveda 
et al. [39] confirmed earlier studies that only the MIB-1 
proliferation index was related to tumour recurrence. In 
their study of 35 giant pituitary adenomas, 60% of pa-
tients with Ki-67 > 3% experienced tumour recurrence, 
as compared to patients with Ki-67 < 3%, in whom 
the recurrence rate was only 6.7%. Grupetta et al. [8] 
confirmed that high Ki-67 predicts tumour regrowth. 
Our rate of recurrence is similar to that found by 
other authors [8, 13, 39], although in their case non-
homogenous groups of different pituitary adenomas 
including GH-secreting tumours were evaluated. 
Studies of the relation between tumour recurrence 
and expression of VEGF and AIP based on IHC are 
sparse and contradictory. A low level of VEGF detected 
PAs with higher rates of regrowth [8]. A low level of 
AIP was associated with higher proliferative activity, 
predicting recurrence in somatotropinomas [40]. 
In our work, the dependence of RR of tumour 
recurrence on the values of markers studied was not 
significant above any of the arbitrarily chosen cut-off 
points, except in the case of AIP above 15%, indicating 
that the chance of recurrence is over three times higher. 
Pre-surgical SSLAR treatment
In our somatotropinomas, SSLAR treatment did not 
significantly affect the expression of any of the studied 
markers. However, VEGF expression was markedly 
lower in the treated vs. non-treated groups of patients. 
Somatostatin analogues in patients with acrome galy 
inhibit TOPO 2A expression, providing molecular evi-
dence of their effectiveness [11, 13]. SSA modulate AIP in 
somatotropinomas, increasing the number of AIP-positive 
cells in immunostaining after lanreotide treatment, com-
pared with patients treated by surgery only [41]. 
The AIP score was up-regulated in SSA-treated 
tumours with better preoperative response such as 
IGF-1 decrease or tumour shrinkage [42], suggesting 
that AIP is involved in the aggressiveness of sporadic 
somatotropinomas [33]. Therefore, AIP expression in 
sporadic somatotropinomas might be a predictor of 
the response to SSA therapy independently of SSTR2 
expression [18].
In patients with invasive adenomas pre-treated 
with SSA before surgery, a decrease in VEGF staining 
was observed [28, 31, 36], as well as lower expression 
of VEGF mRNA [29], suggesting that SSA may inhibit 
angiogenesis through down-regulation of VEGF. How-
ever, studies on SSA modulation of VEGF expression 
are few and inconclusive [29]. 
Ki-67 and TOPO 2A correlation
In our group of somatotropinomas, we found cor-
relation between Ki-67 and TOPO 2A, in line with 
Wolfsberger et al. [14], who found a strong correlation 
between MIB-1 and TOPO 2A expression in PAs, unlike 
Vidal et al. [11]. In contradiction to our study, a signifi-
cant negative correlation between AIP score and Ki-67 
index was also observed [33]. 
Conclusions
Markers of proliferation: Ki-67, TOPO 2A, AIP, and 
VEGF were expressed in over 70% of all somatotropino-
mas. Only Ki-67 and TOPO 2A expression was related to 
tumour size. Ki-67 and TOPO 2A expression was found 
to correlate with tumour invasiveness. 
Since almost all somatotropinomas expressed Ki-67, 
TOPO 2A, AIP, and VEGF, these markers are potential 
targets for non-invasive treatment. 
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